On Wednesday morning, Johnson & Johnson (NYSE:JNJ) published its second-quarter earnings report, but this wasn't greeted ...

The drugmaker posts earnings that narrowly beat expectations and raises its full-year outlook.

Johnson & Johnson, in a motion for order to show cause, insisted that lead plaintiffs’ counsel in the talc multidistrict ...

The drug and medical-device maker raised its forecast for the year after recording higher sales in the second quarter.

Johnson & Johnson JNJ on Wednesday reported second-quarter 2026 results that topped Wall Street estimates and raised its full ...

Johnson & Johnson has been dealing for years with thousands of lawsuits related to its talc-based products, which plaintiffs claim gave them cancer. This issue has somewhat affected the drugmaker's ...

Johnson & Johnson’s strong Q2 earnings, Spravato sales +41%, and raised 2026 EPS guidance. See why this analysis upgrades JNJ ...

Johnson & Johnson's Tom Aelbrecht, N-VA's Jan Jambon, Flemish Minister for Welfare and Culture Caroline Gennez, Deputy department head of the nursing department Siska Van den Bergh, ZAS president Els ...

On Sept. 29, 1982, Mary Kellerman woke up feeling sick. The 12-year-old girl from Elk Grove Village, a suburb of Chicago, asked her parents to stay home from school, and they gave her one ...

Johnson & Johnson (NYSE: JNJ) recently reported its Q2 results, with revenues aligning and earnings exceeding our estimates. The company reported revenue of $22.4 billion and adjusted earnings of ...

Add Yahoo as a preferred source to see more of our stories on Google. On Sept. 29, 1982, Mary Kellerman woke up feeling sick. The 12-year-old girl from Elk Grove Village, a suburb of Chicago, asked ...